Concentra Group (CON) Reports Next Week: What to Expect
Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concentra Group Guides Higher On Acquisitions And Fundamental Improvement
Concentra Group Holdings Parent, Inc. is expanding through acquisitions, boosting its national footprint and patient volume, with recent deals driving higher revenue and operational leverage. The U.S. occupational health market is growing steadily, and Concentra's diverse service offerings and broad employer relationships provide strong competitive advantages. Financials are solid: stable margins, robust free cash flow, low stock-based compensation, and a reasonable valuation versus industry peers support further upside.
Concentra Group (CON) Matches Q2 Earnings Estimates
Concentra Group (CON) came out with quarterly earnings of $0.37 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.49 per share a year ago.
Earnings Preview: Concentra Group (CON) Q2 Earnings Expected to Decline
Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concentra (CON) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Concentra (CON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?
Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Wall Street Analysts Believe Concentra (CON) Could Rally 27.1%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Concentra (CON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Concentra (CON) Upgraded to Buy: Here's Why
Concentra (CON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CON vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Does Concentra (CON) Have the Potential to Rally 30.84% as Wall Street Analysts Expect?
The mean of analysts' price targets for Concentra (CON) points to a 30.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Concentra Group (CON) Tops Q1 Earnings and Revenue Estimates
Concentra Group (CON) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.47 per share a year ago.
